Chinese Journal of Stroke ›› 2018, Vol. 13 ›› Issue (04): 364-371.DOI: 10.3969/j.issn.1673-5765.2018.04.012
Previous Articles Next Articles
Received:
2017-12-26
Online:
2018-04-20
Published:
2018-04-20
李威,刘新峰
通讯作者:
刘新峰 xfliu2@vip.163.com
李威, 刘新峰. 急性缺血性卒中治疗时间窗的研究进展[J]. 中国卒中杂志, 2018, 13(04): 364-371.
[1] WANG Y,LIAO X,ZHAO X,et al. Usingrecombinant tissue plasminogen activator to treatacute ischemic stroke in China:analysis of theresults from the Chinese National Stroke Registry(CNSR)[J]. Stroke,2011,42(6):1658-1664.[2] LIU L,WANG D,WONG K S,et al. Stroke andstroke care in China:huge burden,significantworkload,and a national priority[J]. Stroke,2011,42(12):3651-3654.[3] The National Institute of Neurological Disordersand Stroke rt-PA Stroke Study Group. Tissueplasminogen activator for acute ischemic stroke[J].N Engl J Med,1995,333(24):1581-1587.[4] FONAROW G C,SMITH E E,SAVER J L,etal. Timeliness of tissue-type plasminogenactivator therapy in acute ischemic stroke:patientcharacteristics,hospital factors,and outcomesassociated with door-to-needle times within 60minutes[J]. Circulation,2011,123(7):750-758.[5] POWERS W J,DERDEYN C P,BILLER J,et al.2015 American Heart Association/American StrokeAssociation Focused Update of the 2013 Guidelinesfor the Early Management of Patients With AcuteIschemic Stroke Regarding Endovascular Treatment:A Guideline for Healthcare Professionals Fromthe American Heart Association/American Stroke Association[J]. Sroke,2015,46(10):3020-3035.[6] HERRERA M,GÁLLEGO J,MUÑOZ R,et al.Reperfusion in acute ischaemic stroke:present andfuture[J]. An Sist Sanit Navar,2008,31(Suppl 1):31-46.[7] ASTRUP J,SIESJÖ B K,SYMON L. Thresholds incerebral ischemia-the ischemic penumbra[J]. Stroke,1981,12(6):723-725.[8] 吴江. 经病学[M]. 2版. 北京:人民卫生出版社,2010:158-166.[9] WAHLGREN N,AHMED N,DÁVALOS A,etal. Thrombolysis with alteplase for acute ischaemicstroke in the Safe Implementation of Thrombolysisin Stroke-Monitoring Study(SITS-MOST):anobservational study[J]. Lancet,2007,369(9558):275-282.[10] HACKE W,KASTE M,FIESCHI C,et al.Intravenous thrombolysis with recombinant tissueplasminogen activator for acute hemispheric stroke.The European Cooperative Acute Stroke Study(ECASS)[J]. JAMA,1995,274(13):1017-1025.[11] HACKE W,KASTE M,FIESCHI C,et al.Randomised double-blind placebo-controlledtrial of thrombolytic therapy with intravenousalteplase in acute ischaemic stroke(ECASS Ⅱ).Second European-Australasian Acute Stroke StudyInvestigators[J]. Lancet,1998,352(9136):1245-1251.[12] CLARK W M,WISSMAN S,ALBERS G W,etal. Recombinant tissue-type plasminogen activator(Alteplase)for ischemic stroke 3 to 5 hoursafter symptom onset. The ATLANTIS Study:arandomized controlled trial. Alteplase Thrombolysisfor Acute Noninterventional Therapy in IschemicStroke[J]. JAMA,1999,282(21):2019-2026.[13] HACKE W,KASTE M,BLUHMKI E,et al.Thrombolysis with alteplase 3 to 4.5 hours afteracute ischemic stroke[J]. N Engl J Med,2008,359(13):1317-1329.[14] WAHLGREN N,AHMED N,DÁVALOS A,etal. Thrombolysis with alteplase 3-4.5 h after acuteischaemic stroke(SITS-ISTR):an observationalstudy[J]. Lancet,2008,372(9646):1303-1309.[15] IST-3 collaborative group,SANDERCOCK P,WARDLAW J M,et al. The benefits and harms ofintravenous thrombolysis with recombinant tissueplasminogen activator within 6 h of acute ischaemicstroke(the third international stroke trial [IST-3]):a randomised controlled trial[J]. Lancet,2012,379(9834):2352-2363.[16] ALBERS G W,THIJS V N,WECHSLER L,etal. Magnetic resonance imaging profiles predictclinical response to early reperfusion:the diffusionand perfusion imaging evaluation for understandingstroke evolution(DEFUSE)study[J]. Ann Neurol,2006,60(5):508-517.[17] DAVIS S M,DONNAN G A,PARSONS M W,etal. Effects of alteplase beyond 3 h after stroke inthe Echo planar Imaging Thrombolytic EvaluationTrial(EPITHET):a placebo-controlled randomisedtrial[J]. Lancet Neurol,2008,7(4):299-309.[18] HACKE W,ALBERS G,AI-RAWI Y,et al. TheDesmoteplase in Acute Ischemic Stroke Trial(DIAS):a phase Ⅱ MRI-based 9-hour windowacute stroke thrombolysis trial with intravenousdesmoteplase[J]. Stroke,2005,36(1):66-73.[19] UYTTENBOOGAART M,DE KEYSERJ,LUIJCKX G J,et al. Thrombolysis for acuteischemic stroke[J]. Curr Top Med Chem,2009,9(14):1285-1290.[20] HACKE W,FURIAN A J,AI-RAWI Y,et al.Intravenous desmoteplase in patients with acuteischaemic stroke selected by MRI perfusiondiffusionweighted imaging or perfusion CT(DIAS-2):a prospective,randomised,double-blind,placebo-controlled study[J]. Lancet Neurol,2009,8(2):141-150.[21] ALBERS G W,VON KUMMER R,TRUELSEN T,et al. Safety and efficacy of desmoteplase given 3-9h after ischaemic stroke in patients with occlusionor high-grade stenosis in major cerebral arteries(DIAS-3):a double-blind,randomised,placebocontrolledphase 3 trial[J]. Lancet Neurol,2015,14(6):575-584.[22] DEL ZOPPO G J,HIGASHIDA R T,FURIANA J,et al. PROACT:a phase II randomized trialof recombinant pro-urokinase by direct arterialdelivery in acute middle cerebral artery stroke.PROACT Investigators. Prolyse in Acute CerebralThromboembolism[J]. Stroke,1998,29(1):4-11.[23] FURLAN A,HIGASHIDA R,WECHSLER L,et al.Intra-arterial prourokinase for acute ischemic stroke.The PROACT Ⅱ study:a randomized controlled trial.Prolyse in Acute Cerebral Thromboembolism[J].JAMA,1999,282(21):2003-2011.[24] OGAWA A,MORI E,MINEMATSU K,etal. Randomized trial of intraarterial infusion ofurokinase within 6 hours of middle cerebral arterystroke:the middle cerebral artery embolism localfibrinolytic intervention trial(MELT)Japan[J].Stroke,2007,38(10):2633-2639.[25] BRODERICK J P,PALESCH Y Y,DEMCHUK A M,et al. Endovascular therapy after intravenous t-PAversus t-PA alone for stroke[J]. N Engl J Med,2013,368(10):893-903.[26] KIDWELL C S,JAHAN R,GORNBEIN J,et al. Atrial of imaging selection and endovascular treatmentfor ischemic stroke[J]. N Engl J Med,2013,368(10):914-923.[27] CICCONE A,VALVASSORI L,NICHELATTIM,et al. Endovascular treatment for acute ischemicstroke[J]. N Engl J Med,2013,368(10):904-913.[28] BERKHEMER O A,FRANSEN P S,BEUMER D,et al. A randomized trial of intraarterial treatmentfor acute ischemic stroke[J]. N Engl J Med,2015,372(1):11-20.[29] CAMPBELL B C,MITCHELL P J,KLEINIG T J,et al. Endovascular therapy for ischemic stroke withperfusion-imaging selection[J]. N Engl J Med,2015,372(11):1009-1018.[30] SAVER J L,GOYAL M,BONAFE A,et al. Stentretrieverthrombectomy after intravenous t-PA vs.t-PA alone in stroke[J]. N Engl J Med,2015,372(24):2285-2295.[31] JOVIN T G,CHAMORRO A,COBO E,et al.Thrombectomy within 8 hours after symptom onsetin ischemic stroke[J]. N Engl J Med,2015,372(24):2296-2306.[32] GOYAL M,DEMCHUK A M,MENON B K,etal. Randomized assessment of rapid endovasculartreatment of ischemic stroke[J]. New Engl J Med,2015,372(11):1019-1030.[33] SAVER J L,GOYAL M,VAN DER LUGT A,et al.Time to treatment with endovascular thrombectomyand outcomes from ischemic stroke:a metaanalysis[J]. JAMA,2016,316(12):1279-1288.[34] NOGUEIRA R G,JADHAV A P,HAUSSEN D C,et al. Thrombectomy 6 to 24 hours after stroke witha mismatch between deficit and infarct[J]. N Engl JMed,2018,378(1):11-21. |
[1] | LU Yan, YANG Baorong, HUANG Xiangping, YANG Guangui, CHEN Shengwen, LI Jianrong, ZENG Xiaoming. MRI-Guided Thrombolysis beyond Time Window in Acute Ischemic Stroke in a County-Level Hospital: A Case-Control Study [J]. Chinese Journal of Stroke, 2022, 17(12): 1321-1326. |
[2] | XIANG Wei, XU Luyao, ZHANG Manman, WEI Hongchun, LIANG Zhigang. The Frequency and Influencing Factors of Asymmetrical Prominent Veins Sign on Susceptibility-Weighted Imaging in Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(10): 1097-1102. |
[3] | ZHANG Boyu, GUO Yucheng, CUI Yuxia, LI Yingli, LYU Yumei. Seeking Medical Services Decision-Making Status and Relevant Influencing Factors in Patients with Acute Ischemic Stroke: A Review [J]. Chinese Journal of Stroke, 2022, 17(10): 1127-1132. |
[4] | WU Tingting, LIU Yafei, YAN Shixi, WU Yiping, ZHANG Zhongbo, ZAHNG Hanfei, FANG Pinping. Application of “Internet Plus” in Emergency Care of Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(10): 1133-1138. |
[5] | ZHENG Wei, ZHAI Huazheng, CHEN Mengmeng, WANG Jingye. Efficacy and Safety of Direct Thrombectomy versus Bridging Therapy for Acute Ischemic Stroke: A Meta-Analysis [J]. Chinese Journal of Stroke, 2022, 17(07): 720-729. |
[6] | ZHOU Juan, TAN Yunbin, WANG Tiejun, SHI Fuming, YU Ping. Incidence and Influencing Factors of Anxiety and Depression in Caregivers of Patients with Acute Ischemic Stroke during Hospitalization [J]. Chinese Journal of Stroke, 2022, 17(07): 764-768. |
[7] | XUAN Guiying, FAN Caili, XUAN Lixia, ZHAO Qianqian, LI Xuemei. Analysis of Reasons for Loss of Follow-up among Acute Ischemic Stroke Patients during the COVID-19 Pandemic [J]. Chinese Journal of Stroke, 2022, 17(06): 648-652. |
[8] | ZHANG Dong, LI Zhizhang, MA Ruinan, YUE Yunhua. Correlation between Stress Hyperglycemia Ratio and Clinical Prognosis of Patients with Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(05): 483-490. |
[9] | HUANG Yan, FU Xuejun, SHI Huijie, ZOU Liangyu. Correlation between Triglyceride-Glucose Index and Neurological Function Impairment after Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(03): 251-257. |
[10] | LIU Zhong, LIU Yuanyuan, XU Shaofeng, GUO Wei, KANG Hai. Correlation Analysis of Systemic Immune-Inflammatory Index with Severity and Prognosis of Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(03): 285-291. |
[11] | GUO Songtao, E Bu, LI Zhiqiang, JIANG Hao, XU Yuzhu, SUN Jian, SHI Jianmin, WU Xi, GUO Wei. Advances in the Application of 5G Mobile Stroke Unit [J]. Chinese Journal of Stroke, 2022, 17(02): 113-117. |
[12] | HUO Xiaochuan, LI Xiaoqing, MIAO Zhongrong, Expert Committee for Neurointervention Quality Control of National Center for Healthcare Quality Management in Neurological Diseases, Endovascular Treatment Working Committee of National Action for Quality Improvement of Acute Cerebral Infarction Reperfusion Therapy. A Survey of Current Practice in Acute Ischemic Stroke Endovascular Treatment in China in 2020 [J]. Chinese Journal of Stroke, 2022, 17(01): 56-65. |
[13] | CHEN Zhengyu, CHEN Guofang, CHEN Tong, MA Dongjiao. Influencing Factors of Leukoaraiosis at Different Brain Regions in Patients with Intravenous Thrombolysis for Acute Ischemic Strok [J]. Chinese Journal of Stroke, 2021, 16(12): 1248-1252. |
[14] | CAO Shuangshuang, ZHANG Xiaoyan, WANG Jianwei, ZHAO Lei, CHEN Hongbing, WANG Mingyu. The Related Factors of Early Neurological Deterioration after Intravenous Thrombolysis in Patients with Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2021, 16(12): 1253-1258. |
[15] | ZHANG Xin-Miao, WANG Chun-Juan, YANG Xin, GU Hong-Qiu, JIANG Ying-Yu, WANG Yi-Long, ZHAO Xing-Quan, LI Zi-Xiao, WANG Yong-Jun. Safety of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Antithrombotic Therapy before Stroke Onset [J]. Chinese Journal of Stroke, 2021, 16(11): 1110-1114. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||